Company intelligence / Profile preview
Biodexa Pharmaceuticals
- Ownership
- Public · BDRX
- Development stage
- Phase 1
Overview
The lead program, eRapa™ for FAP, has completed Phase II with positive data at six and twelve months. A registrational Phase III trial protocol has been finalized following FDA guidance. The study will enroll approximately 168 patients across the US and Europe, supported by significant grant funding. Other programs are advancing through early clinical development.[6][9]
- Therapeutic areas
- GastroenterologyOncologyEndocrinology
- Modalities
- Small molecules (e.g., rapamycin/sirolimus, tolimidone)[1][7]Nanotechnology-based formulations[1]
- Industry
- Biotech
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $619.9K
- Total revenue
- $0
- Enterprise value
- $-7.8M
Beyond the preview
Go deeper on Biodexa Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biodexa Pharmaceuticals.